Effects of daunomycin implants on filtering surgery outcomes in rabbits

Current Eye Research

Volumn 17, Issue 8, 1998, Pages 844-850

  Morales, Jose ^a   Kelleher, Peter J ^b   Campbell, David ^a   Crosson, Craig E ^a  

^a TEXAS TECH UNIVERSITY   (United States)

^b Houston Biotechnology Incorporated   (United States)

Author keywords

Daunomycin; Glaucoma filtering surgery; Hyaluronic acid; Intraocular pressure; Rabbit

Indexed keywords

DAUNORUBICIN; HYALURONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONJUGATION; DRUG EFFICACY; DRUG IMPLANT; DRUG RELEASE; FILTERING OPERATION; GLAUCOMA SURGERY; INTRAOCULAR PRESSURE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SURVIVAL TIME;

ANIMALS; ANTERIOR EYE SEGMENT; ANTIBIOTICS, ANTINEOPLASTIC; DAUNORUBICIN; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; FILTERING SURGERY; HALF-LIFE; HYALURONIC ACID; INTRAOCULAR PRESSURE; RABBITS; TREATMENT OUTCOME;

EID: 0031812226     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1076/ceyr.17.8.844.5149     Document Type: Article

References (28)

1. Gressel MG, Parrish RK. II, Folberg R. 5-fluorouracil and glaucoma filtering surgery: L. An animal model. Ophthalmology. 1984;91:378-383.
2. The Fluorouracil Filtering Surgery Study Group. Three-year follow-up of the fluorouracil filtering surgery study. Am J Ophthalmol. 1993;115:82-92.
3. The Fluorouracil Filtering Surgery Study Group. Five-year follow-up of the fluorouracil filtering surgery study group. Am J Ophthalmol. 1996;121:349-366.
4. Addicks EM, Quigley HA, Green WR, Robin AL. Histologic characteristics in filtering blebs. Arch Ophthalmol. 1983;101:795-798.
5. Kitazawa Y, Suemori-Matsushita H, Yamamoto T, Kawasa K. Low-dose and high-dose mitomycin trabeculectomy as an initial surgery in primary open-angle glaucoma. Ophthalmology. 1993;100:1624-1628.
6. Demailly P, Kvetz G. Daunorubicin versus 5-Fluoro-Uracil in surgical treatment of primary open angle glaucoma: a prospective study. International Ophthalmology. 1992;16:367-370.
7. Skuta GL, Beeson CC, Higginbotham EJ, et al. Intraoperative Mitomycin versus postoperative 5-Fluorouracil in high-risk glaucoma filtering surgery. Ophthalmology. 1992;99:438-444.
8. Weinreb RN. Adjusting the dose of 5-Fluorouracil after filtration surgery to minimize side effects. Ophthalmology. 1987;94:564-570.
9. Pastor SA, Williams R, Hetherington J, Hoskins HD, Goodman D. J Glaucoma. 1993;2:112-113.
10. Zacharia PT, Depperman SR, Schuman JS. Ocular hypotony after trabeculectomy with mitomycin C. Am J Ophthalmol. 1993;116:314-326.
11. Singh J, O'Brien C, Chawla HB. Success rate and complications of intraoperative 0.2 mg/ml mitomycin C in trabeculectomy surgery. Eye. 1995;9:460-466.
12. Higginbotham EJ, Stevens RK, Musch DC, et al. Blebrelated endophthalmitis after trabeculectomy with mitomycin C. Ophthalmology. 1996;103:650-656.
13. Calabrisi P, Parks RE Jr. Antiproliferative agents and drugs used for immunosuppression. In: Oilman AG, Goodman LS, Rail TW, Murad F, eds. The Goodman and Gilman's Pharmacological Basis of Therapeutics. 7th ed. New York: Macmillan; 1985:1283-1285.
14. Santana M, Wiedemann P; Kirmani M, et al. Daunomycin in the treatment of experimental proliferative vitreoretinopathy: retinal toxicity of intravitreal daunomycin in the rabbit. Graefe's Arch Clin Exp Ophthalmol. 1984;221:210-213.
15. Khawly JA, Saloupis P, Hatchell DL, Machemer R. Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy. Graefe's Arch Clin Exp Ophthalmol. 1991;229:464-467.
16. Rabowsky JH, Dukes AJ, Lee DA, Leong KW. The uses of bioerodible polymers and daunorubicin in glaucoma filtration surgery. Ophthalmology. 1996;103:800-807.
17. Yu Q, Toole BP. Biotinylated hyaluronan as a probe for detection of binding proteins in cells and tissues. Biotechniques. 1995;19:122-124.
18. Hurwitz E, Wilchek M, Pitha J. Soluble macromolecules as carriers for daunorubicin. J Appl Biochem. 1980;2:25-35.
19. Pouyani T, Prestwich GD. Functionalized derivatives of hyaluronic acid oligosaccharides: drug carriers and novel biomaterials. Bioconjugate Chem. 1994;5:339-347.
20. Migdal C, Hitchings R. Control of chronic simple glaucoma with primary medical, surgical and laser treatment. Trans Ophthalmol Soc UK. 1986;105:653-656.
21. Jay JL, Allan D. The benefit of early trabeculectomy versus conventional management in primary open angle glaucoma relative to severity of disease. Eye. 1989;3:528-535.
22. Lee DA, Flores RA, Anderson PJ, et al. Glaucoma filtration surgery in rabbits using bioerodible polymers and 5-fluorouracil. Ophthalmology. 1987;94:1523-1530.
23. Lee DA, Leong KW, Panek WC, Eng CT, Glasgow BJ. The use of bioerodible polymers and 5-fluorouracil in glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 1988;29:1692-1697.
24. Jampel HD, Leong KW, Dunkelburger GR, Quigley HA. Glaucoma filtration surgery in monkeys using 5-fluorouridine in polyanhydride disks. Arch Ophthlamol. 1990;108:430-435.
25. Charles JB, Ganthier R Jr., Wilson MR, et al. Use of bioerodible polymers impregnated with mitomycin in glaucoma filtration surgery in rabbits. Ophthalmology. 1991;98:503-508.
26. Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability: effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci. 1995;36:1893-1903.
27. Cordeiro MF, Constable PH, Alexander RA, Bhattacharya SS, Khaw PT. Effect of varying the mitomycin-C treatment area in glaucoma filtration surgery in the rabbit. Invest Opthalmol Vis Sci. 1997;38:1639-1646.
28. Lee DA, Lee TC, Cortes AE, Kitada S. Effects of mithramycin, mitomycin, daunorubicin, and bleomycin on human subconjunctival fibroblast attachment and proliferation. Invest Opthalmol Vis Sci. 1990;31:2136-2144.